['A) THIS TABLE IS NOT ALL INCLUSIVE.', 'B) IN A STUDY OF 6 NORMAL VOLUNTEERS, A SIGNIFICANT INCREASE IN TACROLIMUS ORAL BIOAVAILABILITY (14\xc2\xb15% VS. 30\xc2\xb18%) WAS OBSERVED WITH CONCOMITANT KETOCONAZOLE ADMINISTRATION (200 MG). THE APPARENT ORAL CLEARANCE OF TACROLIMUS DURING KETOCONAZOLE ADMINISTRATION WAS SIGNIFICANTLY DECREASED COMPARED TO TACROLIMUS ALONE (0.430\xc2\xb10.129 L/HR/KG VS. 0.148\xc2\xb10.043 L/HR/KG). OVERALL, IV CLEARANCE OF TACROLIMUS WAS NOT SIGNIFICANTLY CHANGED BY KETOCONAZOLE COADMINISTRATION, ALTHOUGH IT WAS HIGHLY VARIABLE BETWEEN PATIENTS.', 'C) LANSOPRAZOLE (CYP2C19, CYP3A4 SUBSTRATE) MAY POTENTIALLY INHIBIT CYP3A4-MEDIATED METABOLISM OF TACROLIMUS AND THEREBY SUBSTANTIALLY INCREASE TACROLIMUS WHOLE BLOOD CONCENTRATIONS, ESPECIALLY IN TRANSPLANT PATIENTS WHO ARE INTERMEDIATE OR POOR CYP2C19 METABOLIZERS, AS COMPARED TO THOSE PATIENTS WHO ARE EFFICIENT CYP2C19 METABOLIZERS.', 'CALCIUM', 'ANTIFUNGAL', 'MACROLIDE', 'CHANNEL BLOCKERS', 'AGENTS', 'ANTIBIOTICS', 'DILTIAZEM', 'CLOTRIMAZOLE', 'CLARITHROMYCIN', 'NICARDIPINE', 'FLUCONAZOLE', 'ERYTHROMYCIN', 'NIFEDIPINE', 'ITRACONAZOLE', 'TROLEANDOMYCIN', 'VERAPAMIL', 'KETOCONAZOLE B VORICONAZOLE', '', 'GASTROINTESTINAL', 'OTHER', '', 'PROKINETIC AGENTS', 'DRUGS', '', 'CISAPRIDE', 'BROMOCRIPTINE', '', 'METOCLOPRAMIDE', 'CHLORAMPHENICOL', '', '', 'CIMETIDINE', '', '', 'CYCLOSPORINE', '', '', 'DANAZOL', '', '', 'ETHINYL ESTRADIOL', '', '', 'METHYLPREDNISOLONE', '', '', 'LANSOPRAZOLE C', '', '', 'OMEPRAZOLE', '', '', 'PROTEASE INHIBITORS', '', '', 'NEFAZODONE', '', '', 'MAGNESIUM-ALUMINUM-HYDROXIDE', '']